Association between blood pressure classification defined by the 2017 ACC/AHA guidelines and coronary artery calcification progression in an asymptomatic adult population

Ki-Bum Won 1,2, Donghee Han2,3, Su-Yeon Choi4, Eun Ju Chun5, Sung Hak Park6, Hae-Won Han7, Jidong Sung8, Hae Ok Jung9, and Hyuk-Jae Chang2,*

Aims
Coronary artery calcium score (CACS) is widely used for cardiovascular risk stratification in asymptomatic population. We assessed the association of new blood pressure (BP) classification using the 2017 American College of Cardiology/American Heart Association guidelines with coronary artery calcification (CAC) progression according to age in asymptomatic adults.

Methods and results
Overall, 10,839 asymptomatic Korean adults (23.4% aged <45 years) who underwent at least two CACS evaluations for health check-up were enrolled. Participants were categorized by age (<45 and >45 years) and BP [normal (<120/<80 mmHg, untreated), elevated (120–129/<80 mmHg, untreated), Stage 1 hypertension (untreated BP 130–139/80–89 mmHg) or Stage 2 hypertension (BP >140/>90 mmHg or anti-hypertensive use)] groups. CAC progression was defined as a difference of >2.5 between the square root of the baseline and follow-up CACS. During a mean 3.3-year follow-up, the incidence of CAC progression was 13.5% and 36.3% in individuals aged <45 and >45 years, respectively. After adjustment for age, sex, diabetes, dyslipidaemia, obesity, current smoking, and baseline CACS, hazard ratios (95% confidence interval) for CAC progression in elevated BP, Stage 1 hypertension, and Stage 2 hypertension compared to normal BP were 1.43 (0.96–2.14) (P = 0.077), 1.64 (1.20–2.23) (P = 0.002), and 2.38 (1.82–3.12) (P < 0.001) in the <45 years group and 1.11 (0.95–1.30) (P = 0.179), 1.17 (1.04–1.32) (P = 0.009), and 1.52 (1.39–1.66) (P < 0.001) in the >45 years group, respectively.

Conclusion
Newly defined Stage 1 hypertension is independently associated with CAC progression in asymptomatic adults regardless of age.

* Corresponding author. Tel: +82(0)222288460, Fax: +82(0)23932041, Email: hjchang@yuhs.ac
© The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
Introduction

High blood pressure (BP) is one of the most important risk factors for cardiovascular (CV) morbidity and mortality. The American College of Cardiology (ACC)/American Heart Association (AHA) have recently lowered the BP thresholds for the diagnosis of hypertension; newly defining Stage 1 hypertension as a systolic BP of 130–139 mmHg or a diastolic BP of 80–89 mmHg. This reinforced criterion for hypertension could emphasize the significance of BP in preventing adverse CV events. However, the new guidelines could also lead to the overdiagnosis of hypertension and result in unnecessary treatment, particularly in young adults or adults with a low CV risk burden. Several recent studies have reported the usefulness of this new guideline, but there has been no consensus in clinical practice. Moreover, the additional values of reinforced BP classification for the risk of atherosclerosis progression beyond traditional risk factors remain uncertain.

In the asymptomatic population, coronary artery calcium score (CACS) has been widely used for CV risk stratification because CACS provides strong prognostic information across diverse age groups, sex, ethnicities, and baseline traditional risk factors. Furthermore, the progression of coronary artery calcification (CAC) is known as a significant predictor of mortality. Recent data from the Heinz Nixdorf Recall study revealed that CAC progression had an independent prognostic benefit in the absence of heavy CAC at baseline, suggesting that early detection of the presence and progression of CAC is important in reducing the risk of adverse clinical events in the asymptomatic population. However, data regarding the significance of the newly defined Stage 1 hypertension and the risk of CAC progression among different age groups are limited. Therefore, this study aimed to evaluate the association between the reinforced criteria for hypertension and CAC progression according to age in asymptomatic Korean adults.

Methods

Study population

In this observational, multicentre study, 10,839 self-referred asymptomatic Korean adults were enrolled from the Korea Initiatives on Coronary Artery Calcification registry. All participants had undergone at least two CAC scan examinations and had available data regarding BP, history of hypertension, and anti-hypertensive use between December 2012 and August 2016. All data were obtained during visits to the six healthcare centres. Self-reported medical questionnaires were used to retrieve information on the medical history. BP was measured using an automatic manometer on the right arm after resting for at least 5 min. Height and weight were measured with the participants wearing light clothing without shoes. Body mass index (BMI) was calculated as weight (kg)/height (m²). All blood samples, including total cholesterol, triglyceride, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein

Keywords

Blood pressure • Hypertension • Coronary artery calcium score
cholesterol (LDL-C), creatinine, glucose, and glycated haemoglobin A1C (HbA1C) were obtained after at least 8 h of fasting.

Participants were categorized by age (<45 and ≥45 years) and BP [normal BP (untreated systolic/diastolic <120/ <80 mmHg), elevated BP (untreated systolic/diastolic = 120–129/<80 mmHg)], Stage 1 hypertension (untreated systolic/diastolic BP = 130–139/80–89 mmHg) or Stage 2 hypertension (systolic/diastolic BP ≥ 140/>90 mmHg or taking anti-hypertensive medication). Diabetes was defined either as a fasting glucose level of ≥126 mg/dL, HbA1C of ≥6.5%, a previous diagnosis of diabetes, and/or taking anti-diabetic medication. Dyslipidaemia was defined as a total cholesterol level of >240 mg/dL, a serum LDL-C level of ≥130 mg/dL, a serum HDL-C level of ≤40 mg/dL, a serum triglyceride level of ≥150 mg/dL, and/or taking anti-hyperlipidaemic medication. Obesity was defined as a BMI of ≥25.0 kg/m². Current smoking was defined as those who currently smoked or had smoked until 1 month before the study.

Coronary artery calcium score was measured using the scoring system previously described by Agatston et al. Coronary artery calcification progression was determined using the SQRT method, defined as a difference of ≥2.5 between the square root (\sqrt{\text{baseline CACS}}) of the baseline and follow-up CACS (\sqrt{\text{transformed CACS}}), considering the proportion of CACS of 0 at baseline in the present study. Annualized \Delta transformed CACS was defined as \Delta transformed CACS divided by the inter-scan period. Computed tomography (CT) to evaluate CACS was performed using scanners with a >16-slice multi-detector Siemens 16-slice Sensation (Siemens, Forchheim, Germany), Philips Brilliance 256 iCT (Philips Healthcare, Cleveland, OH), Philips Brilliance 40-channel multi-detector CT (Philips Healthcare), and GE 64-slice Lightspeed (GE Healthcare, Milwaukee, WI, USA). All CAC scans were performed using a scan protocol of standard ECG-triggering methods. For each centre, CACS was evaluated by the experienced CV radiologists and the results of CACS measurement were reported in the electronic health record, per routine clinical care in South Korea. Informed consent was obtained from each participant. The appropriate institutional review board committees of each centre approved the protocol of the present study.

Statistical analysis
Continuous variables are presented as mean ± standard deviation. Categorical variables are presented as absolute values and percentage. One-way analysis of variance was used to compare continuous variables. The χ² or Fisher’s exact test was used to compare categorical variables, as appropriate. Univariate linear regression analysis was performed to identify the association of clinical variables with the annualized \Delta transformed CACS. Multiple Cox regression models were used to assess the risk of CAC progression in elevated BP, Stage 1 hypertension, and Stage 2 hypertension versus normal BP. Model 1 provided the unadjusted hazard ratio (HR) and Model 2 provided the adjusted HR after considering the traditional risk factors of age, sex, diabetes, dyslipidaemia, obesity and current smoking, and baseline CACS. All statistical analyses were performed using SAS version 9.1.3 (SAS Institute Inc., Cary, NC, USA). A P-value of <0.05 was considered significant in all analyses.

Results
Baseline characteristics
The mean age of the 10,839 participants (9,154 men, 84.5%) was 51.5 ± 8.6 years. The proportion of participants aged >45 years was 76.6%. The proportions of participants with normal BP, elevated BP, Stage 1 hypertension, and Stage 2 hypertension were 38.2%, 8.9%, 17.0%, and 35.9%, respectively. The overall prevalence of diabetes, dyslipidaemia, obesity, and current smoking were 14.3%, 68.1%, 22.8%, and 28.6%, respectively. Age, BMI, levels of triglyceride, glucose, and HbA1C as well as the prevalence of diabetes, dyslipidaemia, and obesity significantly increased with a higher BP classification. In contrast, the levels of HDL-C significantly decreased with a higher BP classification (Table 1).

Among the overall participants, the mean value of baseline CACS was 45.9 ± 174.1, and the proportions of CACS of 0, 1–100, and >100 were 56.5%, 32.9%, and 10.6%, respectively. In participants aged ≤45 years, the mean value of baseline CACS was 6.9 ± 39.9, and the proportions of CACS of 0, 1–100, and >100 were 85%, 13.2%, and 1.8%, respectively. In participants aged >45 years, the mean value of baseline CACS was 57.8 ± 196.1 and the proportions of CACS of 0, 1–100, and >100 were 47.8%, 39.0%, and 13.2%, respectively (Figure 1).

Changes in coronary artery calcification according to the classification of blood pressure
The overall incidence of CAC progression in participants with normal BP, elevated BP, Stage 1 hypertension, and Stage 2 hypertension were 24.5%, 24.6%, 27.0%, and 41.4%, respectively. CAC progression was more frequently observed in participants aged >45 years than in those aged ≤45 years (36.3% vs. 13.5%; P < 0.001). In overall participants, the mean values of annualized \Delta transformed CACS for normal BP, elevated BP, Stage 1 hypertension, and Stage 2 hypertension were 0.48 ± 1.70, 0.49 ± 1.33, 0.60 ± 1.32, and 1.03 ± 2.14, respectively. The mean values of annualized \Delta transformed CACS were significantly different among the BP groups in participants aged ≤45 years (normal BP: 0.17 ± 0.73 vs. elevated BP: 0.24 ± 0.68 vs. Stage 1 hypertension: 0.32 ± 1.11 vs. Stage 2 hypertension: 0.60 ± 1.36; P < 0.001) and in those aged >45 years (normal BP: 0.40 ± 1.15 vs. elevated BP: 0.62 ± 1.55 vs. Stage 1 hypertension: 0.70 ± 1.37 vs. Stage 2 hypertension: 1.09 ± 2.23; P < 0.001) (Figure 2).

Association between clinical variables and annualized \Delta transformed coronary artery calcium score
Table 2 shows that age, male sex, systolic BP, BMI, current smoking, and the serum levels of triglyceride, HDL-C, glucose, and HbA1C were significantly associated with the annualized \Delta transformed CACS in participants aged ≤45 years and >45 years. Diastolic BP and the serum levels of LDL-C had significant associations with the annualized \Delta transformed CACS in participants aged ≤45 years only (Table 2).

Association between blood pressure and the risk of coronary artery calcification progression
The results of the Cox regression models for the association between BP and the risk of CAC progression are presented in Table 3. Model 1 showed that the risk of CAC progression was significantly increased in those with elevated BP, Stage 1 hypertension, and Stage 2 hypertension compared with those with normal BP in participants aged ≤45 years. In participants aged >45 years, the risk of CAC progression was significantly increased in Stages 1 and 2 hypertension,
| Table 1  | Baseline characteristics |
|---------|--------------------------|

|                | Overall (N = 10 839) | Normal BP (N = 4138) | Elevated BP (N = 968) | Stage 1 Hypertension (N = 1838) | Stage 2 Hypertension (N = 3895) | Overall P-value |
|----------------|-----------------------|-----------------------|-----------------------|----------------------------------|----------------------------------|-----------------|
| Age (years)    | 51.5 ± 8.6            | 49.6 ± 7.8            | 49.7 ± 8.8            | 50.2 ± 8.1                       | 54.6 ± 8.7                       | <0.001          |
| Age >45 years, n (%)    | 8304 (76.6)           | 2947 (71.2)           | 643 (66.4)            | 1335 (72.6)                      | 3379 (86.8)                      | <0.001          |
| Male, n (%)     | 9154 (84.5)           | 3304 (79.8)           | 818 (84.5)            | 1639 (89.2)                      | 3393 (87.1)                      | <0.001          |
| Systolic BP (mmHg) | 119.6 ± 15.0           | 106.9 ± 8.1           | 123.6 ± 2.9           | 126.8 ± 7.8                      | 128.6 ± 15.8                     | <0.001          |
| Diastolic BP (mmHg) | 74.9 ± 10.6           | 66.9 ± 6.8            | 73.4 ± 4.4            | 81.9 ± 4.6                       | 80.6 ± 11.1                      | <0.001          |
| BMI (kg/m²)     | 24.5 ± 2.8            | 23.6 ± 2.5            | 24.5 ± 2.7            | 24.7 ± 2.6                       | 25.4 ± 2.8                       | <0.001          |
| Diabetes, n (%) | 1546 (14.3)           | 372 (9.0)             | 93 (9.6)              | 195 (10.6)                       | 886 (22.7)                       | <0.001          |
| Dyslipidaemia, n (%)       | 7377 (68.1)           | 2558 (61.8)           | 638 (65.9)            | 1270 (69.1)                      | 2911 (74.7)                      | <0.001          |
| Obesity, n (%) | 4526 (41.8)           | 1217 (29.4)           | 391 (40.4)            | 818 (44.5)                       | 2100 (54.0)                      | <0.001          |
| Current smoking, n (%)  | 3018 (28.6)           | 1311 (32.5)           | 273 (28.8)            | 481 (26.7)                       | 953 (25.3)                       | <0.001          |
| Total cholesterol (mg/dL) | 197.4 ± 34.1          | 196.2 ± 33.6          | 200.8 ± 33.2          | 203.1 ± 33.5                     | 195.2 ± 34.7                     | <0.001          |
| Triglyceride (mg/dL)    | 142.1 ± 89.5          | 129.2 ± 78.6          | 140.4 ± 88.0          | 151.5 ± 104.0                    | 151.9 ± 91.6                     | <0.001          |
| HDL-C (mg/dL)         | 53.7 ± 16.4           | 54.6 ± 16.4           | 54.0 ± 17.2           | 53.4 ± 15.9                      | 52.6 ± 16.5                      | <0.001          |
| LDL-C (mg/dL)         | 121.5 ± 31.8          | 121.8 ± 31.5          | 123.3 ± 32.1          | 124.7 ± 31.4                     | 119.3 ± 32.2                     | <0.001          |
| Glucose (mg/dL)       | 98.0 ± 20.5           | 94.0 ± 17.8           | 96.8 ± 19.2           | 98.7 ± 20.7                      | 102.2 ± 22.6                     | <0.001          |
| HbA1C (%)             | 5.7 ± 0.7             | 5.6 ± 0.7             | 5.6 ± 0.7             | 5.6 ± 0.7                        | 5.8 ± 0.8                        | <0.001          |

Values are presented as the mean ± standard deviation or number (%).

*P < 0.05 vs. stage 1 hypertension in the Bonferroni’s post hoc test.

BMI, body mass index; BP, blood pressure; HbA1C, glycated haemoglobin A1C; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.
but not in those with an elevated BP, compared with those with normal BP levels. In model 2, Stages 1 and 2 hypertension, but not elevated BP, were significantly associated with an increased risk of CAC progression compared with those with normal BP levels after adjusting for age, sex, diabetes, dyslipidemia, obesity, current smoking, and baseline CACS in participants aged <45 years and >45 years. The results of the restricted cubic spine analysis for the association between systolic and diastolic BP and the risk of CAC progression in overall participants are presented in Supplementary material online, Figure S1.

**Discussion**

With the community-based cohort data from six health care centres in South Korea, Stage 1 hypertension, newly defined by the 2017 ACC/AHA guideline, was independently associated with an increased risk of CAC progression in asymptomatic adults aged <45 years as well as in those aged >45 years. Considering that CAC progression is a useful prognostic marker in asymptomatic participants, the recently reinforced BP classification system using the ACC/AHA guideline may help stratify CV risk beyond the traditional risk factors.

Most young adults with Stage 1 hypertension, as defined by the new (2017) ACC/AHA guideline, were considered as having a low CV risk burden and would not be recommended for pharmacological treatment. If Stage 1 hypertension is not related to the risk of adverse clinical events in young adults or adults with low CV risk burden, overdiagnosis of hypertension related to the reinforced BP criteria can result in unnecessary treatment and increased medical costs. In the recent Coronary Artery Risk Development in Young Adults study, Yano et al. reported that elevated BP, Stage 1 hypertension, and Stage 2 hypertension occurring before 40 years of age were associated with a significantly higher risk of CV events than normal BP (HR 1.67, 1.75, and 3.49, respectively) during a median follow-up of 18.8 years. A pooled prospective cohort analysis of 154,407 Chinese adults identified consistent results, where Stage 1 hypertension was significantly associated with an increased risk of CV mortality, particularly among young adults and those without a history of CV disease during a total follow-up of 1,718,089 person-years. Consistently, Son et al. reported that compared with a normal BP, Stages 1 and 2 hypertension were associated with an increased risk of subsequent CV events among 2,488,101 Korean adults aged 20–39 years. These findings imply that the recent ACC/AHA BP classification system can assist CV risk stratification.

Coronary artery calcium score has been widely used for estimating CV risk in the asymptomatic adult population due to its powerful prognostic information across diverse clinical conditions. In particular, the low cost, low inter- and intra-observer variability, high reproducibility across various vendors, and easily obtainable images make CACS an attractive tool for CV risk stratification. A recent cross-sectional study of 96,166 Koreans reported that the higher BP categories defined by the 2017 ACC/AHA guidelines were positively related to prevalent CAC and that correlation began in the elevated BP category, even in a young, low-risk adult population. However, data on the significance of the reinforced BP criteria regarding CAC changes are limited. Budoff et al. previously identified that CAC progression, particularly when defined by the SQRT method, added incremental predictive value for all-cause mortality over baseline CACS, time between scans, demographics, and CV risk factors. Recently, Lehmann et al. reported that CAC progression did not have a predictive value for the risk of adverse CV events in cases of CACS of >400 at baseline. In the present study, the proportion of participants with baseline CACS of >400 was only 2.6%. Despite a significant difference in the incidence of CAC progression between participants aged <45 years and those aged >45 years, annual changes in CACS were found to be increased with a higher BP classification in both age groups. Moreover, stage considering the traditional risk factors and baseline CACS together in both age groups. Based on the results from the Heinz Nixdorf Recall study, which emphasized the significance of prehypertension defined by the Joint National Committee 7 guideline on accelerated CAC progression, a stricter BP control to meet the enhanced criteria for hypertension could attenuate the progression of coronary atherosclerosis. Furthermore, this therapeutic strategy may have benefits for the asymptomatic young adult population, considering that atherosclerotic CV events commonly occur in conditions with low CV risk burden.

The necessity of pharmacological intervention increases in the middle-aged and older population because the prevalence of metabolic abnormalities gradually increases with age. Pharmacological agents could have an effect on the progression of coronary atherosclerosis for this reason, coronary CT angiography (CCTA) has been proposed to have additional benefits over CACS and the traditional risk factors in asymptomatic patients due to its ability of providing more detailed coronary atherosclerotic information, including luminal stenosis severity and plaque composition. However, recent data from the Coronary CT Angiography Evaluation For Clinical Outcomes: An International Multicenter (CONFIRM) registry revealed that further prognostic benefit was not conferred by CCTA when considering the traditional risk factors and CACS in an asymptomatic population during a mean follow-up of 5.9 ± 1.2 years. Compared with the CV risk stratification based on the traditional risk factors and CACS, the role of CCTA may be limited in the asymptomatic adult population.
In contrast to the new ACC/AHA guideline, the 2018 European Society of Cardiology (ESC)/European Society of Hypertension (ESH) guidelines have retained the traditional definition of hypertension. As recent studies have shown the usefulness of CACS use in other diverse clinical situations. It may be possible that CACS helps to identify hypertensive patients who may benefit from intensive BP control and hence reconcile the target BP differences between the ACC/AHA and ESC/ESH guidelines. Further outcome studies are necessary to support this approach.

**Figure 2** Comparison of coronary artery calcification (CAC) changes according to blood pressure (BP) classification.

**Table 2** Association between clinical variables and the annualized \( A \) transformed CACS

|                      | Overall       |                        | Age ≤45 years |                        | Age >45 years |                        |
|----------------------|---------------|------------------------|---------------|------------------------|---------------|------------------------|
|                      | \( \beta \) (95% CI) | \( p \)-value | \( \beta \) (95% CI) | \( p \)-value | \( \beta \) (95% CI) | \( p \)-value |
| Age, per-1 year increase | 0.040 (0.036–0.044) | <0.001 | 0.031 (0.021–0.041) | <0.001 | 0.041 (0.035–0.047) | <0.001 |
| Male sex             | 0.492 (0.398–0.586) | <0.001 | 0.372 (0.275–0.468) | <0.001 | 0.496 (0.376–0.617) | <0.001 |
| Systolic BP          | 0.006 (0.004–0.008) | <0.001 | 0.009 (0.006–0.011) | <0.001 | 0.005 (0.002–0.008) | 0.001 |
| Diastolic BP         | 0.005 (0.002–0.009) | <0.001 | 0.012 (0.008–0.015) | <0.001 | 0.002 (-0.002 to 0.006) | 0.358 |
| BMI, per-1 kg/m\(^2\) increase | 0.059 (0.046–0.071) | <0.001 | 0.047 (0.035–0.059) | <0.001 | 0.061 (0.045–0.077) | <0.001 |
| Current smoking      | 0.102 (0.025–0.179) | 0.009 | 0.124 (0.044–0.204) | 0.002 | 0.160 (0.061–0.259) | 0.002 |
| Triglyceride, per-1 mg/dL increase | 0.001 (0.001–0.002) | <0.001 | 0.002 (0.001–0.002) | <0.001 | 0.001 (0.001–0.002) | <0.001 |
| HDL-C, per-1 mg/dL increase | -0.003 (-0.005 to 0.001) | 0.001 | -0.005 (-0.007 to -0.002) | <0.001 | -0.003 (-0.006 to -0.001) | 0.029 |
| LDL-C, per-1 mg/dL increase | 0.002 (0.001–0.003) | <0.001 | 0.003 (0.002–0.004) | <0.001 | 0.001 (-0.001 to 0.002) | 0.167 |
| Glucose, per-1 mg/dL increase | 0.009 (0.007–0.010) | <0.001 | 0.007 (0.005–0.009) | <0.001 | 0.008 (0.006–0.010) | <0.001 |
| HbA1C, per-1% increase | 0.255 (0.204–0.306) | <0.001 | 0.196 (0.127–0.266) | <0.001 | 0.241 (0.181–0.300) | <0.001 |

BMI, body mass index; BP, blood pressure; CACS, coronary artery calcium score; CI, confidence interval; HbA1C, glycated haemoglobin A1C; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.
There are several limitations to the present study. First, all participants voluntarily visited the hospital for a general health examination. Thus, a selection bias may be present. Second, the proportion of participants aged <45 years was only 23.4%. However, despite the relatively small sample size of participants aged <45 years, the present study identified a significant association between the newly defined Stage 1 hypertension and CAC progression beyond the traditional risk factors in this population. Third, the use of pharmacological agents was not controlled during the follow-up period due to the observational design of this study. Fourth, different CT scanners were used among the participating centres; however, all participants were examined using the same CT scanner with identical ECG-triggering method during the initial and follow-up image acquisitions. In addition, CAC progression was defined using the SQRT method, considering inter-scan variability in the present study. Fifth, the current study did not perform the variability analysis based on the firm evidence regarding variability and reproducibility of CACS measurement. Finally, the generalizability of our results may be limited considering that all participants were Korean.

**Lead author biography**

Ki-Bum Won is Assistant Professor of Cardiology at Ulsan University Hospital, University of Ulsan College of Medicine, South Korea. Dr. Won is an expert in cardiac computed tomography and coronary artery disease. He has been studying metabolic syndrome, diabetes mellitus, and atherosclerosis with non-invasive imaging tools and biomarkers focusing on the primary prevention for over ten years. Dr. Won has published about 40 research papers as first or corresponding author in the field of atherosclerotic cardiovascular disease.

**Conclusions**

Stage 1 hypertension, newly defined by the 2017 ACC/AHA guideline, is independently associated with an increased risk of CAC progression in asymptomatic Korean adults, irrespective of age. The reinforced ACC/AHA guideline for the diagnosis of hypertension may assist CV risk stratification beyond the traditional risk factors in the asymptomatic adult population.

**Supplementary material**

Supplementary material is available at European Heart Journal Open online.

**Acknowledgements**

We acknowledge the help of Eun-Ji Park, The Medical Information Centre of Ulsan University Hospital, who supported this work.

**Author contributions**

All authors have made substantial contributions. KBW performed the statistical analysis. DH, SYC, EJC, SHP, HWH, HOJ and HJC contributed to the data acquisition. KBW and HJC contributed to the interpretation of data. KBW drafted the manuscript. HJC critically revised the manuscript. All authors have read and approved the final manuscript. All authors have also given the final approval and have agreed to be held accountable for all aspects of the work ensuring integrity and accuracy.

### Table 3  Cox regression models for the association between BP and the risk of CAC progression

| Overall | Age <45 years | Age >45 years |
|---------|---------------|---------------|
|         | HR (95% CI)   | P-value       | HR (95% CI)   | P-value       | HR (95% CI)   | P-value       |
| Normal BP | 1              | —             | 1              | —             | 1              | —             |
| Elevated BP | 1.20 (1.04–1.38) | 0.011         | 1.58 (1.06–2.34) | 0.024         | 1.16 (0.99–1.34) | 0.062         |
| Stage 1 hypertension | 1.27 (1.14–1.42) | <0.001         | 1.83 (1.35–2.47) | <0.001         | 1.20 (1.07–1.35) | 0.002         |
| Stage 2 hypertension | 2.09 (1.93–2.26) | 0.001         | 3.12 (2.42–4.02) | <0.001         | 1.84 (1.69–1.99) | <0.001         |
| Elevated BP | 1.14 (0.99–1.31) | 0.077         | 1.43 (0.96–2.14) | 0.077         | 1.11 (0.95–1.30) | 0.179         |
| Stage 1 hypertension | 1.20 (1.08–1.34) | 0.001         | 1.64 (1.20–2.23) | 0.002         | 1.17 (1.04–1.32) | 0.009         |
| Stage 2 hypertension | 1.58 (1.46–1.72) | <0.001         | 2.38 (1.82–3.12) | <0.001         | 1.52 (1.39–1.66) | <0.001         |

BP, blood pressure; CAC, coronary artery calcification; CACS, coronary artery calcium score; CI, confidence interval; HR, hazard ratio.

Model 1: unadjusted.
Model 2: adjusted for age, sex, diabetes, dyslipidaemia, obesity, current smoking, and baseline CACS.
References

1. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Prospective Studies Collaboration. Age specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903–1913.

2. Zhang Y, Jang K, Bo J, Yin L, Chen H, Wang Y, Yu H, Wang X, Li W. PURE: China Investigators. Risk of stroke and coronary heart disease among various levels of blood pressure in diabetic and nondiabetic Chinese patients. J Hypertens 2018;36:93–100.

3. Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension 2018;71:e13–e115.

4. Yano Y, Reis JP, Colangelo LA, Shrimb D, Viera AJ, Allen NB, Gidding SS, Bress AP, Greenland P, Munter P, Liy-Sy-Jones DM. Association of blood pressure classification in young adults using the 2017 American College of Cardiology/American Heart Association blood pressure guideline with cardiovascular events later in life. JAMA 2018;320:1774–1782.

5. Liu N, Yang JJ, Meng R, Pan X-F, Zhang X, He M, Liao Y, Yang L. Risk of strokes and coronary heart disease among various levels of blood pressure in adults defined by 2017 ACC/AHA guidelines with mortality in China: pooled results of 26 population-based cohorts. J Hypertens 2018;36:354–359.

6. Detryan R, Guerci AD, Carr JJ, Bild DE, Burke G, Folsom AR, Liu K, Shea S, Skolos M, Blumenthal S, O’Leary DH, Tracy R, Watson K, Wong ND, Kronmal RA. Coronary calcium as a predictor of coronary events in four racial or ethnic groups. N Engl J Med 2008;358:1336–1345.

7. Erbel R, Möhlenkamp S, Moebus S, Schmermund A, Lehmann N, Stang A, Draganos N, Grönermeier D, Seibel R, Kälsch H, Brücker-Preuss M, Münz M, Kießig J, Jöckel K-H. Coronary risk stratification, discrimination, and reclassification improvement based on quantification of subclinical coronary atherosclerosis: the Heinz Nixdorf Recall study. J Am Coll Cardiol 2010;56:1397–1406.

8. Budoff MJ, Shaw LJ, Liu SJ, Weinstein SR, Tseng PH, Flores FR, Callister TQ, Raggi P, Berman DS, Mosler TP. Long-term prognosis associated with coronary calcium observations from a registry of 25,253 patients. J Am Coll Cardiol 2007;49:1860–1870.

9. Budoff MJ, Hakonarson JE, Nasir K, Shaw LJ, Kinney GL, Chow D, DeMoss D, Nuguri V, Nabavi V, Ratakkoda R, Berman DS, Raggi P. Progression of coronary artery calcium predicts all-cause mortality. JACC Cardiovasc Imaging 2010;3:1229–1236.

10. Lehmann N, Erbel R, Mahabadi AA, Rauwolf M, Möhlenkamp S, Moebus S, Kälsch H, Budde T, Schmermund A, Stang A, Führer-Saleel D, Weimar C, Roggenbuck U, Draganos N, Jöckel KH, Meienert T, Bode FC, de Feyter PJ, Giss durch TQ, Giss durch TQ. Accelerated progression of coronary artery calcium in hypertension but also prehypertension. J Hypertens 2016;34:2233–2242.

11. Muntner P, Carey RM, Gidding S, Jones DW, Talier S, Wright JT, Whelton PK. Potential US population impact of the 2017 ACC/AHA high blood pressure guideline. J Am Coll Cardiol 2018;71:109–116.

12. Lloyd-Jones DM, Hong Y, Labarthe D, Mozaffarian D, Appel LJ, Van Horn L, Greenlund K, Daniels N, Nichol G, Tomasselli GF, Arnett DK, Fonarow GC, Go PM, Lauer MS, Masoudi FA, Robertson RM, Roger V, Schwamm LH, Sorlie P, Yancy CW, Rosamond WD. Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association’s strategic impact goal through 2020 and beyond. Circulation 2010;121:586–613.

13. Leonard MG, Blaha MJ, Budoff MJ, Blankstein R, Sibley CT, Agatston A, Blumenthal RS, Nasir K. Impact of coronary artery calcium on coronary heart disease events in individuals at the extremes of traditional risk factor burden: the multi-ethnic study of atherosclerosis. Eur Heart J 2014;35:2232–2241.

14. Yusuf S, Rangarajan S, Teo K, Islam S, Li W, Liu L, Bo J, Lou Q, Lu F, Liu T, Yu L, Zhang S, Mony P, Swaminathan S, Mohan V, Gupta R, Kumar R, Vijaygakumar K, Lear S, Anand S, Wiegelsoz A, Diaz R, Avezum A, Lopez-Jaramillo P, Lanas F, Yusuf K, Islam N, Isqal R, Rahman O, Rosengren A, Yusufali A, Keliash S, Kruger A, Puon G, Zibua A, Chithamba J, Oga Z, McQueen M, McKee M, Dagenais G. Cardiovascular risk and events in 17 low-, middle-, and high-income countries. N Engl J Med 2017;376:818–827.

15. Lim SD, Shin H, Song JH, Kwak SH, Kang SM, Won Yoon J, Choi SH, Choi SI, Park KS, Lee HK, Jang HC, Koh KK. Increasing prevalence of metabolic syndrome in Korea: the Korean National Health and Nutrition Examination Survey for 1998–2009. Diabetes Care 2011;34:1323–1328.

16. Lee S-E, Chang HJ, Sung JM, Park H-B, Heo R, Rizvi A, Lin FY, Kumar A, Adhamizadeh K, Kim YJ. Coronary plaques and epicardial coronary artery calcium burden: the PARADIGM study. JACC Cardiovasc Imaging 2018;11:1475–1484.

17. Lee S-E, Sung JM, Andreni D, Budoff MJ, Cademartini F, Chinnaian K, Choi JH, Chin C, Conde E, Gottlieb I, Hadamitzky LM, Kim YJ, Lee BK, Chen CJ, Cademartini F, Maffei E, Marques H, Leopold J, Shin S, Choi JH, Chinnaian K, Raff G, Virmani R, Yamada H, Stone PH, Berman DS, Naranja B, Shaw LJ, Bax J, Min JK. Effects of statins on coronary atherosclerotic plaques: the PARADIGM study. JACC Cardiovasc Imaging 2018;11:1475–1484.

18. Lehmann N, Erbel R, Mahabadi AA, Kälsch H, Möhlenkamp S, Moebus S, Stang A, Roggenbuck U, Strukbus KM, Führer-Saleel D, Draganos N, Budde T, Seibel R, Grönermeier D, Jöckel KH, Heinz Nixdorf Recall Study Investigators. Coronary artery calcium screening: current status and recommendations from the European Society of Cardiac Radiology and North American Society for Cardiovascular Imaging. Eur Radiol 2008;18:2785–2807.

19. Budoff MJ, McClelland RL, Chuang H, Wong ND, Carr JJ, Gray MM, Blumenthal RS, Detryan R. Reproducibility of coronary artery calcium plaque with cardiac 64-DMCT: the Multi-Ethnic Study of Atherosclerosis. Am J Roentgenol 2009;192:613–617.

20. Al-Mallah MH. Coronary artery calcium scoring: do we need more prognostic data prior to adoption in clinical practice? JACC Cardiovasc Imaging 2018;11:1807–1809.

21. Lang PJ, Shaw LJ, Liu SJ, Weinstein SR, Tseng PH, Flores FR, Callister TQ, Raggi P, Berman DS, Mosler TP. Long-term prognosis associated with coronary calcium observations from a registry of 25,253 patients. J Am Coll Cardiol 2007;49:1860–1870.

22. Budoff MJ, Hakonarson JE, Nasir K, Shaw LJ, Kinney GL, Chow D, DeMoss D, Nuguri V, Nabavi V, Ratakkoda R, Berman DS, Raggi P. Progression of coronary artery calcium predicts all-cause mortality. JACC Cardiovasc Imaging 2010;3:1229–1236.

23. Lehmann N, Erbel R, Mahabadi AA, Rauwolf M, Möhlenkamp S, Moebus S, Kälsch H, Budde T, Schmermund A, Stang A, Führer-Saleel D, Weimar C, Roggenbuck U, Draganos N, Jöckel KH, Meienert T, Bode FC, de Feyter PJ, Gunstert B, Gützwiller F, Heinen H, Hess O, Klein B, Lowel H, Reiser M, Schmidt G, Schwaiger M, Steinmüller C, Theorell T, Willich SN, Bode C, Berger K, Figulla HR, Hamm C, Hanrather P, Kopacz W, Ringelstein B, Dichgans M, Zeller A. Value of coronary artery calcium measurement for risk prediction of coronary- and cardiovascular events: result of the HNR Study (Heinz Nixdorf Recall). Circulation 2013;127:665–679.

24. American Diabetes Association. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes. 2018. Diabetes Care 2018;41(Suppl 1):S13–27.

25. Shin S, Kim KJ, Chang HJ, Cho I, Kim YJ. Choi B-W, Phee Y, Lim SK, Yang W-L, Shinn J-C, Ha J-W, Jang Y, Chung N. Impact of serum calcium and phosphate on coronary atherosclerosis detected by cardiac computed tomography. J Am Heart 2012;33:2873–2881.

26. Executive summary of the clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. Arch Intern Med 1998;158:1855–1867.
Progression of Atherosclerotic Plaque Determined by Computed Tomographic Angiography Imaging (PARADIGM) study. *Eur Heart J Cardiovasc Imaging* 2019;20:1307–1314.

30. Cho I, Al’Aref SJ, Berger A, Ó Hartaigh B, Gransar H, Valenti V, Lin FY, Achenbach S, Berman DS, Budoff MJ, Callister TQ, Al-Mallah MH, Cademartiri F, Chinnayyan K, Chow BJW, DeLago A, Villines TC, Hadamitzky M, Hausleiter J, Leipsic J, Shaw LJ, Kaufmann PA, Feuchtinger G, Kim YJ, Maffei E, Raff G, Pontone G, Andreini D, Marques H, Rubinshtein R, Chang H-J, Min JK. Prognostic value of coronary computed tomographic angiography findings in asymptomatic individuals: a 6-year follow-up from the prospective multicentre international CONFIRM study. *Eur Heart J* 2018;39:934–941.

31. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement DL, Coca A, de Simone G, Dominiczak A, Kahan T, Mahtoud F, Redon J, Rulope L, Zanchetti A, Kerins M, Kjeldsen SE, Laurent S, Lip GYH, Narkiewicz K, Ruilope L, Zanchetti A, Kerins M, Kjeldsen SE, Laurent S, Lip GYH, Narkiewicz K, Ruilope L. 2018 ESC/ESH Guidelines for the management of arterial hypertension. *Eur Heart J* 2018;39:3021–3104.

32. McEvoy JW, Martin SS, Dardari ZA, Miedema MD, Sandfort V, Yeboah J, Budoff MJ, Goff DC, Pasty BM, Post WS, Nasir K, Blumenthal RS, Blaha MJ. Coronary artery calcium to guide a personalized risk-based approach to initiation and intensification of antihypertensive therapy. *Circulation* 2017;135:153–165.

33. Aljizeeri A, Alsaileek A, Al-Mallah MH. Coronary artery calcium score to guide hypertension therapy. *Atherosclerosis* 2019;282:162–164.

34. Uddin SM, Mirboloulou M, Kianoush S, Orimoloye OA, Dardari Z, Whelton SP, Miedema MD, Nasir K, Rumberger JA, Shaw LJ, Berman DS, Budoff MJ, McEvoy JW, Matsushita K, Blaha MJ, Graham G. Role of coronary artery calcium for stratifying cardiovascular risk in adults with hypertension. *Hypertension* 2019;73:983–989.

35. Hong JC, Blankstein R, Shaw LJ, Padula WV, Arrieta A, Falkow JA, Blumenthal RS, Blaha MJ, Krumholz HM, Nasir K. Implications of coronary artery calcium testing for treatment decisions among statin candidates according to the ACC/AHA cholesterol management guidelines: a cost-effectiveness analysis. *JACC Cardiovasc Imaging* 2017;10:938–952.

36. Spahillari A, Zhu J, Ferket BS, Hunink MGM, Carr JJ, Terry JG, Nelson C, Mwasongwe S, Merz RJ, O’Brien EC, Correa A, Shah RV, Murthy VL, Pandya A. Cost-effectiveness of contemporary statin use guidelines with or without coronary artery calcium assessment in African American individuals. *JAMA Cardiol* 2020;5:871–880.

37. Venkataraman P, Kawakami H, Huynh Q, Mitchell G, Nicholls SJ, Stanton T, Tonkin A, Watts GF, Marwick TH. Cost-effectiveness of coronary artery calcium scoring in people with a family history of coronary disease. *JACC Cardiovasc Imaging* 2021;14:1206–1217.